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moderately hypofractionated RT (65-75.2 Gy at 2.2-2.7 
Gy/fr) in 5 fractions per week.  
Relevant clinical factors were collected for each patient: T 
stage, concomitant morbidities and drugs, androgen 
deprivation (AD), previous surgery, smoking, alcohol, age and 
BMI. Urinary symptoms were self-reported by each patient 
through the International Prostate Symptom Score (IPSS) 
before and after RT; based on previous results, absolute 
(cm2) weekly dose-surface histograms (DSHw) were chosen as 
dosimetry descriptors. 
A multivariate logistic regression (MVR) was performed for 
two endpoints: 1) the onset of moderate-severe urinary 
toxicities at RT end (IPSSend≥15) for a subgroup of patients 
with none/mild symptoms before RT (IPSSbefore<15); 2) the 
worsening of urinary symptoms after RT described by an IPSS 
increase of at least 10 points after RT (DIPSS≥10). 
The choice of relevant factors to be included in the MVR had 
been previously carried out through an in silico methodology 
combining a bootstrap resampling, a backward feature 
selection based on minimization of residuals and a basket and 
network analysis of bootstrapped models. Features with the 
greatest percentage of occurrences (OCC) in the 
bootstrapped models were included in the MVR. A dedicated 
software for data mining (KNIME) was used. 
Results: IPSS scores before and after RT were available for 
429 patients. 
97 out of 385 patients (25%) with none/mild symptoms before 
RT showed IPSSend≥15; while DIPSS≥10 was found in 85/429 
(20%) patients. Results of variable selection and MVR are 
reported in Figure and Table: models with six (AUC=0.70) and 
five variables (AUC=0.66) were considered for the IPSSend≥15 
(1) and DIPSS≥10 (2) endpoints, respectively. 
The most robustly predictive clinical variables were: IPSS 
score before RT (OR=1.17, OCC=92%) in model 1); and AD 
(OR=0.63, OCC=78% and OR=0.49, OCC=72%) and the use of 
anti-hypertensives (OR=2.12, OCC=79% and OR=1.72, 
OCC=40%) present in both models as protective and risk 
factor, respectively. A dosimetric variable was also recovered 
as a risk factor in both models: DSHw at 12.5 Gy (OR=1.02, 






Conclusions: Correlations between clinical/dosimetric 
parameters and the onset or worsening of urinary symptoms 
were studied. 
The role of pre-treatment urinary symptoms was confirmed 
as a risk factor. The medium-high weekly doses and the use 
of anti-hypertensives were found as risk predictors, while AD 
was protective in both analyses. 
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Purpose/Objective: The dose delivered to organs at risk 
differs between patients due to differences in their personal 
anatomies. Such differences may correlate with variations in 
toxicity. For several acute gastrointestinal toxicity endpoints 
we constructed average dose difference maps on the rectal 
surface between the groups of patients with and without 
event. The significance of dose differences was tested. 
Materials and Methods: RTOG (grade ≥1, ≥2) toxicity 
endpoints derived from identical questionnaires were 
available for prostate cancer patients treated to 78Gy in 39 
fractions within two prospective trials, one using 3D-CRT and 
bony set-up correction (n=215), the other using image-guided 
(IG) IMRT with gold markers and reduced PTV margins 
(n=260). Two mappings of the treatment planning dose 
distribution on the delineated rectum surface were defined 
using regular intervals along the central rectum axis. The 
first (rectum) mapping intersects the rectum surface with 
planes perpendicular to this axis, and places the axis origin at 
the half-height of the delineated prostate. The second (anus) 
mapping uses horizontal intersection planes, and places the 
origin at the lowest delineated contour. Dose maps were 
constructed and averaged over patients with and without 
each endpoint, and dose difference maps were generated. 
Significance was tested by normalizing the dose difference to 
the local standard deviation, and calculating p values for the 
maximum normalized difference based on a permutation 
method. Contours were drawn around regions with p<0.05. 
Results: Tighter margins and increased conformity led to 
smaller high dose regions on the anal and rectal surface for 
IG-IMRT patients (Fig. 1a-d), and to lower grade ≥2 GI toxicity 
(29% vs. 49% for 3D-CRT). Significantly higher (p<0.05) local 
dose was found for 3D-CRT patients with proctitis, mucus 
loss, and stool frequency ≥6 in the anus mapping, and for 
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incontinence and mucus loss in the rectum mapping. For the 
IG-IMRT patients only mucus loss was significant in the anus 
mapping, while both mucus loss and proctitis were significant 
in the rectum mapping. Results for proctitis are illustrated 
for 3D-CRT (44% incidence) in the anus mapping (Fig. 1e, 
p=0.01) and for IG-IMRT (27% incidence) in the rectum 
mapping (Fig. 1f, p<0.01). Note that the largest dose 
differences are not necessarily most significant. In a region 
with large dose variations, random permutations can lead to 
large differences by chance. Figs. 1c and 1e indicate an 
effect of the extent of the intermediate dose region around 
the circumference of the anus. Figs. 1b and 1f show the 
effect of a longer intermediate dose region along the central 
axis. 
Conclusions: Significant differences in the local dose to 
rectal and anal surfaces were found between patients with or 
without various GI toxicities. The locations of such 
differences provide clues about variables which are relevant 
to the clinical outcome, and which may serve as a basis for 
subsequent dose-effect modeling. 
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Purpose/Objective: Acute dysphagia is a common toxicity, 
associated with (chemo)radiotherapy for head and neck 
cancer, with substantial quality of life implications. 'Late' 
dysphagia is thought to result predominantly as a 
consequence of acute toxicity and associated interventions. 
There are currently limited dose-response data on radiation-
induced acute dysphagia in the literature. The aim of this 
study was to train and validate NTCP models, providing 
reliable tools to accurately predict the severity of acute 
dysphagia for individual patients. 
Materials and Methods: Predictive models of moderate or 
worse (Common Terminology Criteria for Adverse Events 
grade 2 or 3) and severe (grade 3) acute dysphagia were 
trained using data from six clinical trials featuring a range of 
primary disease sites and treatment techniques. Toxicity 
outcome was defined as the peak grade of toxicity, which 
was scored weekly throughout radiotherapy and up to 4 
weeks post-treatment and additionally at 8 weeks post-
treatment. 266 patients were included in the analysis after 
excluding patients with two or more consecutive missing 
toxicity measurements. Pharyngeal mucosa dose-volume 
parameters, concomitant treatment and clinical factors were 
considered as model covariates. Logistic regression was used 
for classification. Lasso- and ridge-regularisation, class-
weighting and cross-validated grid search were employed. 
The models were validated internally (with nested 5-fold 
stratified shuffle split cross-validation) and externally (on 
independent data) to measure their performance, using area 
under the receiver operating characteristic curve as the 
performance metric. 
Results: Figure 1 summarises the dose-volume data. 
 
Model diagnostics using learning curves showed that the 
severe dysphagia model was under-fitting the data. It was 
thought that this might be due to insufficient 
characterisation of concurrent chemotherapy. The model was 
retrained using 115 patients who did not receive concurrent 
chemotherapy. Table 1 shows the internal and external 
validation scores. 
NTCP model Internal validation 




Moderate or worse 
dysphagia 
0.89 ± 0.07 0.82 




0.67 ± 0.09 0.70 
Table 1: Model performances. 
The models contained a range of dosimetric and other 
variables, with V45 and concurrent chemotherapy having the 
highest regression coefficients for the moderate or worse and 
severe dysphagia models, respectively. 
Conclusions: A high performance NTCP model, capable of 
accurately predicting moderate or worse acute dysphagia for 
individual patients, has been trained and validated. It can 
also be used for informed comparisons of dose distributions 
and treatment strategies. The performance of the severe 
dysphagia model did not improve when trained on 
radiotherapy only patients, suggesting that additional 
